PATENT CLAIM ANALYSIS

Application Number: 15924039
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "001100"]

Abstract:
A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

Claim (Index 20):
The method of  claim 18 , wherein degarelix is administered to the patient as a single dose 3 days before administration of WST11 followed by immediate laser local illumination of the area at 755 nm.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 90.0
- Lexical Diversity: 1.3125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12920088', '14115217', '13447825', '14412235', '15331777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7813443300090473
- 35 USC 102 Novelty (BERT): 0.5315970217849385
- Combined Prediction Score: 0.7563695991866365
- Mean Citation Score: 297.153702
- Max Citation Score: 347.8857
- Similarity Product: 222.58241750316023

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test